CD8A and neoplasm: In a syngeneic mouse model using CT26 colon carcinoma cells, ALX148 reduced myeloid immunosuppression, increased dendritic cell and CD8+ T-cell activation, and decreased tumor growth in combination with anti–PD-1 antibody (21, 22).